Cannabis products are being accepted as legitimate consumer products goods and even medical treatments. The future of cannabis legalization in the United States appears to be one of great promise, and ofalso associated with great significantrisk. Although legislative actions have allowed the majority of cannabis and cannabidiol (CBD) products to be available to consumers, a lack of regulation and oversight has left many questions surrounding patient safety and product quality.  The current state and federal cannabis and medical cannabis laws are overdue for an overhaul. <br/><br/>Federal regulation and pharmaceutical drug development of cannabis, hemp, and cannabinoid products is a complex and poorly understood issue. A clear, multi-path federal regulatory framework may be needed to effectively protect the public’s health and ensure patient safety, product quality, and market access,. By offering multiple pathways to legitimacy and implementing public health policies to control risk, the federal government has an opportunity to systematically examine the potential therapeutic benefits of medical cannabinoid products while protecting patient safety. Legalizing cannabis and cannabinoid products will allow the traditional research and drug development process to occur and may be the only possible way to quiet the allure of the illicit unregulated markets. <br/><br/>

Legalization of cannabinoid products and standardizing drug development: Pros, cons, and implications

ACS Fall 2020 Virtual Meeting

The official archive and repository for all ACS Meetings & Expositions abstracts and select posters or presentations.